5Y Capital, previously known as Morningside Venture Capital, is a private equity and venture capital firm based in Shanghai, China, with additional offices in Beijing and Hong Kong. Founded in 1992, it specializes in early-stage investments across a wide range of sectors, including healthcare, technology, fintech, consumer services, media, and education. The firm manages approximately USD 3 billion in funds, leveraging investments from prominent sovereign wealth funds, family offices, and other institutional investors. With an initial investment threshold of over USD 500,000 per portfolio company, 5Y Capital focuses primarily on opportunities in China and other emerging markets in Asia and the Pacific. It is a subsidiary of the Morningside Group, which has a long-standing commitment to socially responsible investing and philanthropic initiatives, particularly in education and scientific research.
Versant Ventures is a prominent healthcare investment firm founded in 1999 and headquartered in California. The firm specializes in investing across the healthcare sector, focusing on medical devices, biotechnology, and pharmaceuticals at various stages of company development. With $2.3 billion under management and offices in Canada, the U.S., and Europe, Versant Ventures emphasizes the discovery and development of novel therapeutics. The firm has cultivated a team with extensive investment, operational, and scientific expertise, allowing for a hands-on approach to building companies. Since its inception, more than 65 companies backed by Versant have successfully achieved acquisitions or initial public offerings.
Lilly Asia Ventures is the venture capital arm of Eli Lilly and Company, focusing on investments in the life sciences and healthcare sectors across Asia, particularly in China. Founded in 2008, the firm targets promising companies that demonstrate strong management teams and innovative technologies or business models. Lilly Asia Ventures typically invests between $5 million and $15 million per funding round, aiming for a minority stake, usually less than 20 percent, in its portfolio companies. In addition to biopharmaceuticals and biotechnology, the firm also explores opportunities in medical technology, healthcare services, and broader life sciences, including agricultural biotechnology and nutraceuticals. While the primary focus is on China, the firm is open to investment opportunities in other East and South Asian markets.
SOSV is a venture capital firm headquartered in New Jersey, focused on seed-to-growth stage investments in sectors such as biotechnology, hardware, robotics, and cross-border software, particularly in Asia. Established in 1995, SOSV operates several global accelerator programs, including HAX for hardware, IndieBio and RebelBio for life sciences, Chinaccelerator and MOX for cross-border internet, Food-X for disruptive food technologies, and dlab for blockchain innovations. The firm invests in approximately 150 companies annually and emphasizes a strategy that combines early-stage funding with extensive support, facilitating product development, customer acquisition, and scaling. SOSV's commitment to nurturing revolutionary deep technologies and its proven track record position it among the top 10% of venture capital funds worldwide.
Qiming Venture Partners is a prominent venture capital firm founded in 2006, with its headquarters in Shanghai and additional offices in Beijing, Suzhou, and Hong Kong. The firm specializes in investing in early and growth-stage companies across various sectors, including media and internet, information technology, consumer and retail, healthcare, and clean technology. Since its inception, Qiming has established itself as a leading investment firm in China, managing four funds with over $1 billion in assets. The firm is known for its strategic focus on fostering innovation and supporting the growth of young, fast-growing enterprises in the Chinese market.
Ben Franklin Technology Partners of Southeastern Pennsylvania is a non-profit organization established in 1982 that promotes the development and adoption of new technologies in the region. Over the past 30 years, it has emerged as a prominent provider of seed stage capital, investing more than $170 million in over 1,750 technology companies, many of which have achieved significant industry success. In addition to financial support, Ben Franklin fosters university and industry collaborations to expedite the commercialization of scientific innovations. The organization is dedicated to enhancing the regional entrepreneurial ecosystem, creating jobs, and transforming lives through its initiatives.
New Alliance is a private equity and venture capital firm established in 2008, with headquarters in Shanghai, China. The firm focuses on early, growth-stage, and pre-IPO investments across various sectors, including high-end manufacturing, technology, advanced agriculture, consumer goods, information, media, energy, recycling, environmental protection, and modern services. New Alliance typically invests between $4.71 million and $31.41 million in its portfolio companies, aiming to support their development and expansion in competitive markets.
IMM Investment Corp. is an independent private equity and venture capital firm based in Seoul, South Korea, founded in July 1999. The firm specializes in mezzanine investments and focuses on various investment strategies, including mergers and acquisitions, corporate restructuring, and management buyouts. It targets medium-sized companies in sectors such as information technology infrastructure, wireless communications, healthcare, biotechnology, and manufacturing. IMM Investment allocates its growth stage investments primarily to startups, expansion, and mezzanine funding, with a strong emphasis on IT infrastructure, digital hardware, and content creation. The firm actively participates in management and seeks to invest in companies with strong ratings, particularly in regions like Seoul and surrounding provinces.
OrbiMed is a healthcare-focused investment firm with approximately $5 billion in assets under management. Founded in 1989, the firm aims to invest across a diverse range of healthcare companies, from private startups to large multinational corporations. OrbiMed manages various investment vehicles, including venture capital funds under the Caduceus Private Investments series, as well as public equity funds. The firm specializes in a broad array of sectors within the healthcare industry, such as pharmaceuticals, biotechnology, medical devices, and healthcare services. With a global investment strategy, OrbiMed seeks to make significant investments, typically ranging from $3 million to $150 million, with a preference for taking majority stakes in its portfolio companies. The firm operates offices in major financial centers, including New York, San Francisco, Mumbai, Herzliya, Shanghai, and Luxembourg.
Fidelity is a privately owned investment manager based in Boston, providing a wide range of financial services to individual investors, businesses, financial advisors, and institutions. Established in 1946, the firm offers products such as IRAs, 401(k) rollovers, annuities, discount brokerage services, retirement services, estate planning, wealth management, securities execution and clearance, and life insurance. Fidelity manages equity, fixed income, and balanced mutual funds, investing in public equity and fixed income markets globally. The company conducts in-house research to inform its investment strategies, helping over 32 million individuals and managing employee benefit programs for more than 22,000 businesses. Additionally, Fidelity supports over 13,000 financial institutions by providing innovative investment and technology solutions. The firm operates through multiple regional offices and Investor Centers across the United States.